SAR302503

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hematopoietic Neoplasm

Conditions

Hematopoietic Neoplasm

Trial Timeline

Oct 1, 2011 → May 1, 2014

NCT ID

NCT01420783

About SAR302503

SAR302503 is a phase 2 stage product being developed by Bristol Myers Squibb for Hematopoietic Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT01420783. Target conditions include Hematopoietic Neoplasm.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01762462	Phase 1	Completed	Dec 1, 2012	Mar 1, 2013	Hepatic Impairment
NCT01692366	Phase 2	Completed	Nov 1, 2012	Mar 1, 2014	Myelofibrosis
NCT01763190	Phase 1	Completed	Nov 1, 2012	Jul 1, 2013	Renal Impairment
NCT01523171	Phase 2	Completed	Apr 1, 2012	Apr 1, 2014	Hematopoietic Neoplasm
NCT01420783	Phase 2	Completed	Oct 1, 2011	May 1, 2014	Hematopoietic Neoplasm
NCT01420770	Phase 2	Completed	Aug 1, 2011	Apr 1, 2014	Hematopoietic Neoplasm

Competing Products

20 competing products in Hematopoietic Neoplasm

See all competitors

Product	Company	Stage	Hype Score
ASP0113	Astellas Pharma	Phase 2	52
Itacitinib + Corticosteroid	Johnson & Johnson	Phase 2	52
Imipenem/Cilastatin/Relebactam + Cefepime + Meropenem + Piperacillin-Tazobactam + Vancomycin + Daptomycin + Linezolid	Merck	Phase 2	52
caspofungin + liposomal amphotericin B	Merck	Phase 2	52
Efprezimod alfa + Placebo + Methotrexate + Tacrolimus	Merck	Phase 3	77
Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide + Uprosertib	Novartis	Phase 1/2	41
ICL670	Novartis	Approved	85
Blinatumomab + Dexamethasone + Ibrutinib + Nivolumab	Amgen	Phase 2	51
Denosumab	Amgen	Phase 2	51
Remdesivir	Gilead Sciences	Phase 2	51
Inotuzumab Ozogamicin + Vincristine Sulfate Liposome	Pfizer	Phase 1/2	40
SAR302503	Bristol Myers Squibb	Phase 2	51
SAR302503 + Placebo	Bristol Myers Squibb	Phase 3	76
SAR302503	Bristol Myers Squibb	Phase 2	51
Narsoplimab	Omeros Corporation	Pre-clinical	18
SARS-CoV-2 mRNA Vaccine ARCT-021 + Tozinameran	Arcturus Therapeutics	Phase 2	44
Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo	Seres Therapeutics	Phase 1	25
BL-8040 + Placebo	BioLineRx	Phase 1	25
Recombinant Interferon Alfa-2b + Rintatolimod	AIM ImmunoTech	Phase 1/2	33
human lactoferrin peptide 1-11	AM-Pharma	Phase 1/2	33

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved